IP Library Granted Patent US 11,761,007
Granted Patent B2
US 11,761,007 · App. 16/063,107 · Granted Sep 19, 2023

Production of unnatural nucleotides using a CRISPR/Cas9 system

Inventors: Floyd E. Romesberg (La Jolla, CA); Brian Lamb (San Diego, CA); Yorke Zhang (San Diego, CA)
Assignee: THE SCRIPPS RESEARCH INSTITUTE
C12N15/63C12N5/10C12N9/22C12N15/11C12N15/70C12N2310/20C12N2310/3519
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,761,007
App. No.
16/063,107
Granted
Sep 19, 2023
Kind
B2
Abstract

Disclosed herein are methods, cells, engineered microorganisms, and kits for increased production of a nucleic acid molecule that comprises an unnatural nucleotide.

Claims (17)

1. A cell comprising:

(I) a first nucleic acid sequence comprising an unnatural nucleotide, wherein the unnatural nucleotide does not substantially form a base pair with a natural nucleotide; and

(II) a second nucleic acid sequence encoding a CRISPR/Cas system, wherein the CRISPR/Cas system encodes a single guide RNA (sgRNA) comprising a crRNA-tracrRNA scaffold and a target motif that is complementary to a modified nucleic acid sequence, and

wherein the modified nucleic acid sequence is identical to the first nucleic acid sequence except that it comprises: (1) a substitution of the unnatural nucleotide with a natural nucleotide or (2) a single nucleotide deletion at the unnatural nucleotide position.

2. The cell of claim 1 , wherein one or more plasmids comprise the second nucleic acid sequence encoding the CRISPR/Cas system and the first nucleic acid sequence comprising the unnatural nucleotide.

3. The cell of claim 1 , wherein the modified nucleic acid comprises a substitution of the unnatural nucleotide with a natural nucleotide.

4. The cell of claim 1 , wherein the sgRNA further comprises a protospacer adjacent motif (PAM) recognition element.

5. The cell of claim 4 , wherein a nucleotide within the target motif that recognizes the substituted natural nucleotide of the modified nucleic acid sequence is located between 3 to 22, between 5 to 20, between 5 to 18, between 5 to 15, between 5 to 12, or between 5 to 10 nucleotides from the 5′ terminus of the PAM recognition element.

6. The cell of claim 1 , wherein the CRISPR/Cas system comprises a wild-type Cas9 polypeptide.

7. The cell of claim 1 , wherein the unnatural nucleotide comprises an unnatural base selected from

8. The cell of claim 1 , further comprising a third nucleic acid sequence that encodes an additional single guide RNA (sgRNA) comprising a crRNA-tracrRNA scaffold.

9. The cell of claim 1 , wherein the first nucleic acid sequence comprising the unnatural nucleotide further comprises an additional unnatural nucleotide.

10. The cell of claim 1 , wherein the cell is E. coli.

11. A cell comprising:

(I) a first nucleic acid sequence comprising an unnatural nucleotide, wherein the unnatural nucleotide does not substantially form a base pair with a natural nucleotide; and

(II) one or more second nucleic acid sequences encoding a CRISPR/Cas system, wherein the CRISPR/Cas system encodes two or more single guide RNAs (sgRNAs), each of which comprises a crRNA-tracrRNA scaffold and wherein each sgRNA comprises a target motif that is complementary to a modified nucleic acid sequence, and

wherein the modified nucleic acid sequence is identical to the first nucleic acid sequence except that it comprises: (1) a substitution of the unnatural nucleotide with a natural nucleotide or (2) a single nucleotide deletion at the unnatural nucleotide position.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2018
From: ROMESBERG, FLOYD E.; LAMB, BRIAN; ZHANG, YORKE
To: THE SCRIPPS RESEARCH INSTITUTE
Reel/Frame 047779/0361 →
Continuity (2)
Provisional Application 62269890 · Dec 18, 2015
Related Publication 20200377877A1 · Dec 3, 2020
Cited By (1)
US 12,319,944